Recent advances in carbohydrate-based cancer vaccines
- 27 Downloads
Cancer is a complex multifactorial disease for which many promising therapeutic strategies such as immunotherapy are emerging. Malignant cells frequently express aberrant cell surface carbohydrates, which differentiate them from normal “healthy” cells. This characteristic presents a window for the development of synthetic carbohydrate antigen-based cancer vaccines which can be recognized by the immune system and can bring about T cell-dependent immune responses. Antibodies generated against the carbohydrate antigens partake in the inactivation of carbohydrate-decorated cancer cells, by slowing down tumor cell growth and inducing cancer cell apoptosis. Novel synthetic strategies for carbohydrate antigens have led to several synthetic cancer vaccine candidates. In the present review, we describe the latest progress in carbohydrate-based cancer vaccines and their clinical evaluation in various cancers.
KeywordsCancer vaccines Carbohydrate Immunotherapy Tumor-associated carbohydrate antigens
This work was supported by Zhejiang Provincial Science and Technology Projects (Grant Nos. 2017C33213, LGD19H160001 and 2017C37159), National Natural Science Foundation of China (Grant Nos. 81772537, and 81374014).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Abbas M, Ahmed A, Khan GJ et al (2018) Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer. Curr Probl Cancer. https://doi.org/10.1016/j.currproblcancer.2018.08.003 Google Scholar
- Andtbacka RH, Agarwala SS, Ollila DW et al (2016) Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Head Neck 38:1752–1758. https://doi.org/10.1002/hed.24522 CrossRefGoogle Scholar
- Bauer TM, El-Rayes BF, Li X et al (2013) Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer 119:285–292. https://doi.org/10.1002/cncr.27734 CrossRefGoogle Scholar
- Bennaceur K, Popa I, Portoukalian J, Berthier-Vergnes O, Peguet-Navarro J (2006) Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis. Int Immunol 18:879–886. https://doi.org/10.1093/intimm/dxl024 CrossRefGoogle Scholar
- Bergquist JR, Puig CA, Shubert CR et al (2016) Carbohydrate antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a National Cancer Database Study. J Am Coll Surg 223:52–65. https://doi.org/10.1016/j.jamcollsurg.2016.02.009 CrossRefGoogle Scholar
- Chapman PB, Morrissey DM, Panageas KS et al (2000) Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin+ QS21 vaccine: a dose-response study. Clin Cancer Res 6:874–879Google Scholar
- Chen J, Cheng L, Xie Z, Li Z (2015) Impact of preoperative oral liquid carbohydrate on postoperative insulin resistance in gastric cancer patients and its associated study. Zhonghua Wei Chang Wai Ke Za Zhi 18:1256–1260Google Scholar
- Eggermont AM, Suciu S, Rutkowski P et al (2013) Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J Clin Oncol 31:3831–3837. https://doi.org/10.1200/JCO.2012.47.9303 CrossRefGoogle Scholar
- Furukawa K, Tanemura M, Miyoshi E, Eguchi H, Nagano H, Matsunami K, Nagaoka S, Yamada D, Asaoka T, Noda T, Wada H, Kawamoto K, Goto K, Taniyama K, Mori M, Doki Y (2017) A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes. PLoS ONE 12(10):e0184901CrossRefGoogle Scholar
- Sartorius B, Sartorius K, Aldous C, Madiba TE, Stefan C, Noakes T (2016) Carbohydrate intake, obesity, metabolic syndrome and cancer risk? A two-part systematic review and meta-analysis protocol to estimate attributability. BMJ Open 6:e009301. https://doi.org/10.1136/bmjopen-2015-009301 CrossRefGoogle Scholar
- Tsoukalas N, Kostakis ID, Giaginis C et al (2017) Carcinoembryonic antigen and carbohydrate antigen 19-9 serum levels in non-small cell lung cancer. J BUON 22:1390–1394Google Scholar
- Tsuchida T, Ravindranath MH, Saxton RE, Irie RF (1987) Gangliosides of human melanoma: altered expression in vivo and in vitro. Cancer Res 47:1278–1281Google Scholar